Related Experiment Video
Updated: May 28, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Flecainide in Structural Heart Disease: Reconsidering Its Role in Contemporary Arrhythmia Management
Paschalis Karakasis1, Konstantinos Grigoriou2, Panagiotis Theofilis3
1Second Department of Cardiology, Hippokration General Hospital, Medical School, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece.
Life (Basel, Switzerland)
|May 27, 2026
Summary
Flecainide, a potent antiarrhythmic drug, may be safely used in select patients with structural heart disease, challenging long-standing contraindications. Current evidence suggests benefits outweigh risks in carefully chosen individuals, warranting reassessment of guidelines.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Flecainide use in structural heart disease has been restricted for decades due to the Cardiac Arrhythmia Suppression Trial.
- This trial's findings have led to a broad safety paradigm potentially exceeding its original scope.
Purpose of the Study:
- To re-evaluate the role of flecainide in patients with structural heart disease.
- To contrast historical restrictions with current evidence on flecainide's safety and efficacy.
Main Methods:
- Review of historical data and the Cardiac Arrhythmia Suppression Trial.
- Analysis of emerging observational and early prospective data on flecainide use in specific structural heart disease phenotypes.
- Consideration of advances in cardiac imaging and risk stratification.
Main Results:
- Flecainide remains effective for atrial fibrillation and selected ventricular arrhythmias in patients without structural abnormalities.
- Emerging data suggest potential benefits in carefully selected patients with stable coronary artery disease, preserved left ventricular function, arrhythmogenic right ventricular cardiomyopathy, and PVC-induced cardiomyopathy.
- No clear signal of excess proarrhythmia or mortality observed in these selected groups.
Conclusions:
- Flecainide is not uniformly contraindicated in all structural heart disease.
- A phenotype-specific reassessment of flecainide's role is supported by current evidence.
- Further prospective studies are needed to validate current guideline restrictions in modern clinical practice.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:28Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.